Inland Northwest Research | Spokane, WA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria
-Huntington's disease (HD) gene expansion mutation carrier status with a CAP score of 400-500 inclusive
Either:
Key Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
300 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Reference Study ID Number: BN42489. https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal